Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jamie Reindel

Nurse Practitioner Lima, OH Nurse Practitioner

NPI 1336164755 CMS profile 11021618

2745 Fort Amanda Rd, Lima, OH 45805

Open in the dashboard

General payments

$4,184

308 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamie Reindel of Lima, OH is reported in the CMS Open Payments database as having received $4,184 across 308 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $267 14
2024 General $114 6
2023 General $1,075 75
2022 General $1,533 116
2021 General $1,196 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Reindel
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jamie Reindel were reported at $267. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jamie Reindel Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,196 $135 $40–$426 $132
2022 $1,533 $152 $48–$470 $149
2023 $1,075 $166 $54–$529 $160
2024 $114 $173 $55–$556 $164
2025 $267 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $711 63 payments
  2. Novo Nordisk Inc $699 68 payments
  3. Lilly USA, LLC $408 26 payments
  4. AstraZeneca Pharmaceuticals LP $336 20 payments
  5. Pfizer Inc. $210 12 payments
  6. Amgen Inc. $153 10 payments
  7. Biohaven Pharmaceuticals, Inc. $152 13 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $150 9 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $141 15 payments
  10. Exact Sciences Corporation $133 7 payments
  11. Other $1,090 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,184 308 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $397 36 payments
  2. Ozempic $373 34 payments
  3. NURTEC ODT $293 28 payments
  4. VRAYLAR $250 21 payments
  5. UBRELVY $241 23 payments
  6. FARXIGA $234 14 payments
  7. MOUNJARO $178 11 payments
  8. Saxenda $162 18 payments
  9. TRULICITY $147 10 payments
  10. JARDIANCE $146 9 payments
  11. Other $3,088 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

5,682

Median for Nurse Practitioner: 389

Drug cost

$554,789

Median for Nurse Practitioner: $21,885

Branded share of claims

18.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 94 $116,149
Jardiance Empagliflozin Brand 52 $82,132
Mounjaro Tirzepatide Brand 63 $75,039
Eliquis Apixaban Brand 44 $42,726
Januvia Sitagliptin Phosphate Brand 37 $40,428
Trulicity Dulaglutide Brand 34 $38,948
Vraylar Cariprazine Hcl Brand 13 $20,326
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $17,125
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 20 $16,180
Linzess Linaclotide Brand 18 $14,505

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$44,142

Of which drugs: $5,047

Medicare patients

190

Average age 71

Services billed

7,316

105 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Diabetes 32%
Ischemic heart disease 29%
COPD 24%
Depression 24%
Chronic kidney disease 21%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 25 25 $2,046
Injection, methylprednisolone acetate, 1 mg J1010 Office 39 6,400 $630
Injection, methylprednisolone acetate, 80 mg J1040 Office 17 32 $93
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 47 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $18
$18 63 —
RYBELSUS
  • Novo Nordisk Inc $10
$10 — —
Ozempic
  • Novo Nordisk Inc $10
$10 94 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record